Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2010 May;9(5):387-98. doi: 10.1038/nrd2896.

Alzheimer's disease: strategies for disease modification.

Author information

  • 1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. citronma@lilly.com

Abstract

Alzheimer's disease is the largest unmet medical need in neurology. Current drugs improve symptoms, but do not have profound disease-modifying effects. However, in recent years, several approaches aimed at inhibiting disease progression have advanced to clinical trials. Among these, strategies targeting the production and clearance of the amyloid-beta peptide - a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis - are the most advanced. Approaches aimed at modulating the abnormal aggregation of tau filaments (another key feature of the disease), and those targeting metabolic dysfunction, are also being evaluated in the clinic. This article discusses recent progress with each of these strategies, with a focus on anti-amyloid strategies, highlighting the lessons learned and the challenges that remain.

PMID:
20431570
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk